Erste Group Bank Issues Optimistic Estimate for NVO Earnings

Novo Nordisk A/S (NYSE:NVO) – Research analysts at Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for Novo Nordisk A/S in a report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $3.20 per share for the year, up from their prior forecast of $3.18. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.38 per share.

NVO has been the topic of several other research reports. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Down 1.4%

Shares of NYSE NVO opened at $49.61 on Monday. The stock has a market cap of $221.52 billion, a price-to-earnings ratio of 11.65, a PEG ratio of 4.59 and a beta of 0.77. The business has a 50 day simple moving average of $46.16 and a 200 day simple moving average of $45.78. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $71.79. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Loomis Sayles & Co. L P grew its holdings in Novo Nordisk A/S by 6.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after purchasing an additional 969,916 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after buying an additional 717,719 shares during the last quarter. Morgan Stanley lifted its stake in shares of Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after buying an additional 428,660 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $287,660,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators approved Wegovy as the first GLP-1 obesity tablet, giving Novo Nordisk a new oral option that could expand the company’s reach beyond injectable treatments. Wegovy Pill in Europe – Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug
• Positive Sentiment: Citi raised its price target on Novo Nordisk ahead of Q2 results, citing strong Wegovy pill launch trends and lifting its sales and earnings estimates for the next several years. Citi lifts Novo Nordisk target on strong GLP-1 pill launch
• Positive Sentiment: Prescription data cited in recent commentary suggests oral Wegovy is gaining traction quickly in the U.S., with most new scripts coming from patients new to GLP-1 therapy, which could mean market expansion rather than cannibalization. Novo Nordisk’s Rally Has Room To Run Driven By Oral Wegovy’s Momentum
• Positive Sentiment: Novo Nordisk also expanded its diabetes portfolio in China by launching Kyinsu through Fangzhou’s AI-driven Internet hospital platform, potentially improving access and adding another growth channel. Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China
• Neutral Sentiment: Analysts and media commentary note that while the Wegovy pill improves Novo’s product mix, the company still faces intense competition in the GLP-1 market, keeping the longer-term outlook mixed. Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?
• Neutral Sentiment: Novo Nordisk also continued its share repurchase program, which can support the stock, but this is a routine capital-allocation update rather than a major new catalyst. Novo Nordisk A/S – share repurchase programme

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.